The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
EZFB significantly improved survival outcomes compared with regorafenib in patients with mCRC as a third-line treatment, with a manageable safety profile. Further investigation is warranted, given the clinically meaningful improvements in progression-free survival and overall survival.
Authors
- Yong Sang Hong (ORCID: https://orcid.org/0000-0001-5672-0072)
- Zev A. Wainberg (ORCID: https://orcid.org/0000-0002-7142-1246)
- François Ghiringhelli (ORCID: https://orcid.org/0000-0002-5465-8305)
- Vivek Khemka
- Mathew Boakye
- Jonathan D. Mizrahi (ORCID: https://orcid.org/0000-0002-3710-9742)
- Brandon Beagle
- S. W. Han
- Soohyeon Lee
- Tingting Zhao
- Keun-Wook Lee
- Scott Kopetz
- David Tougeron
- Antoine Italiano
- Michael Cecchini
Institutions
- University of Seoul (KR)
- Ochsner Health System (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of California, Los Angeles (US)
- Korea University (KR)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- Yale University (US)
- University of Ulsan (KR)
- Centre Georges François Leclerc (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Institut Bergonié (FR)
- Pulse Biosciences (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3727
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00